Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia
Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a ...
The 'game-changing' treatment for schizophrenia
US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...
BioSpace2d
5 Schizophrenia Candidates Chasing BMS’ KarXT
As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...
BioSpace2d
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access ...
Medscape5d
Will 'Game-Changer' Antipsychotic Live Up to the Hype?
The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...
Magazine: Enhancing therapy adherence with prodrugs
Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing ...
Schizophrenia: the new drug set to tackle the ‘cancer of psychiatry’
But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...